Preexisting heart failure plus COVID-19 is a bad combination for mortality and heart and kidney injury from the virus, researchers reported in ESC Heart Failure.
Congenital heart disease patients have had relatively low rates of symptomatic COVID-19, but those with genetic syndromes and adults with advanced physiological stage were more likely to have moderate or severe infections. (Journal of the American Heart Association)
The Journal of the American College of Cardiology released a series reviewing the coronavirus’s effects on the heart and risks to heart patients. See this, this, and this.
Big babies are more likely to develop atrial fibrillation later in life. (Cardiovascular Business)
In news from the virtual TCT Connect meeting:
- Intravascular ultrasound-guided drug-eluting stent implantation had less target vessel failure than angiography-guided procedures in 3-year results from ULTIMATE. (JACC: Cardiovascular Interventions)
- Highly complex, high bleeding risk patients did as well at 1 year as patients without a history of atrial fibrillation or complex lesions after stopping dual antiplatelet therapy 1 month after getting a Resolute Onyx drug-eluting stent. (Cath Lab Digest)
Heart attack in younger women was associated with more long-term mortality and less invasive treatment versus men. (ESCardio.org)
An academic-industry coalition, led by the Cardiac Safety Research Consortium and supported by the FDA, said it’s developing the first national pediatric cardiac screening database.
The FDA warned five companies over dietary supplements containing cesium chloride, which can cause arrhythmia, cardiac arrest, QT prolongation, and death. (Cardiovascular Business)
The 2019 assessment of the Global Burden of Disease Study pointed out that “[m]ost alarmingly, the mortality decreases in cardiovascular diseases of the past half a century have slowed substantially, or even reversed,” in wealthier nations. (The Lancet)
The FDA cleared:
- GE Healthcare’s Ultra Edition, an artificial intelligence package for its Vivid cardiovascular ultrasound systems (MassDevice)
- Livmor’s Halo wearable atrial fibrillation detection system (MassDevice)
Inclisiran got an initial greenlight from an advisory body to European regulators for treating high cholesterol or mixed dyslipidemia in adults; the drug is awaiting word from the FDA for the same indication, expected before the end of 2020. (Pharmaphorum)
European regulators also cleared the BioFreedom Ultra drug-coated coronary stent system, Biosensors announced.
Source: MedicalNewsToday.com
